全文获取类型
收费全文 | 1532篇 |
免费 | 9篇 |
学科分类
工业技术 | 1541篇 |
出版年
2023年 | 4篇 |
2020年 | 4篇 |
2019年 | 6篇 |
2018年 | 6篇 |
2017年 | 6篇 |
2016年 | 11篇 |
2014年 | 12篇 |
2013年 | 21篇 |
2012年 | 8篇 |
2011年 | 13篇 |
2010年 | 17篇 |
2009年 | 14篇 |
2008年 | 16篇 |
2007年 | 9篇 |
2006年 | 23篇 |
2005年 | 10篇 |
2004年 | 17篇 |
2003年 | 11篇 |
2002年 | 10篇 |
2001年 | 13篇 |
2000年 | 11篇 |
1999年 | 34篇 |
1998年 | 307篇 |
1997年 | 210篇 |
1996年 | 123篇 |
1995年 | 75篇 |
1994年 | 62篇 |
1993年 | 83篇 |
1992年 | 18篇 |
1991年 | 11篇 |
1990年 | 18篇 |
1989年 | 19篇 |
1988年 | 20篇 |
1987年 | 10篇 |
1986年 | 17篇 |
1985年 | 18篇 |
1984年 | 10篇 |
1983年 | 16篇 |
1982年 | 15篇 |
1981年 | 14篇 |
1980年 | 10篇 |
1979年 | 3篇 |
1978年 | 13篇 |
1977年 | 55篇 |
1976年 | 97篇 |
1975年 | 5篇 |
1974年 | 5篇 |
1973年 | 4篇 |
1970年 | 5篇 |
1968年 | 3篇 |
排序方式: 共有1541条查询结果,搜索用时 0 毫秒
71.
The crystal structure of recombinant wild-type green fluorescent protein (GFP) has been solved to a resolution of 1.9 A by multiwavelength anomalous dispersion phasing methods. The protein is in the shape of a cylinder, comprising 11 strands of beta-sheet with an alpha-helix inside and short helical segments on the ends of the cylinder. This motif, with beta-structure on the outside and alpha-helix on the inside, represents a new protein fold, which we have named the beta-can. Two protomers pack closely together to form a dimer in the crystal. The fluorophores are protected inside the cylinders, and their structures are consistent with the formation of aromatic systems made up of Tyr66 with reduction of its C alpha-C beta bond coupled with cyclization of the neighboring glycine and serine residues. The environment inside the cylinder explains the effects of many existing mutants of GFP and suggests specific side chains that could be modified to change the spectral properties of GFP. Furthermore, the identification of the dimer contacts may allow mutagenic control of the state of assembly of the protein. 相似文献
72.
MJ Clemons E Marshall J Dürig K Watanabe A Howell D Miles H Earl J Kiernan A Griffiths K Towlson P DeTakats NG Testa M Dougal MG Hunter LM Wood LG Czaplewski A Millar TM Dexter BI Lord 《Canadian Metallurgical Quarterly》1998,92(5):1532-1540
BB-10010 is a variant of the human form of macrophage inflammatory protein-1alpha (MIP-1alpha), which has been shown in mice to block the entry of hematopoietic stem cells into S-phase and to increase their self-renewal capacity during recovery from cytotoxic damage. Its use may constitute a novel approach for protecting the quality of the stem cell population and its capacity to regenerate after periods of cytotoxic treatment. Thirty patients with locally advanced or metastatic breast cancer were entered into the first randomized, parallel group controlled phase II study. This was designed to evaluate the potential myeloprotective effects of a 7-day regimen of BB-10010 administered to patients receiving six cycles of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) chemotherapy. Patients were randomized, 10 receiving 100 microgram/kg BB-10010, 11 receiving 30 microgram/kg BB-10010, and nine control patients receiving no BB-10010. BB-10010 was well-tolerated in all patients with no severe adverse events related to the drug. Episodes of febrile neutropenia complicated only 4% of the treatment cycles and there was no difference in incidence between the treated and nontreated groups. Studies to assess the generation of progenitor cells in long-term bone marrow cultures were performed immediately preceding chemotherapy and at the end of six dosing cycles in 18 patients. Circulating neutrophils, platelets, CD 34(+) cells, and granulocyte/macrophage colony-forming cell (GM-CFC) levels were determined at serial time points in cycles 1, 3, and 6. The results showed similar hemoglobin and platelet kinetics in all three groups. On completion of the six treatment cycles, the average pretreatment neutrophil levels were reduced from 5.3 to 1.7 x 10(9)/L in the control patients and from 4.3 to 1.9 and 4.5 to 2.5 x 10(9)/L in the 30/100 microgram/kg BB-10010 groups, respectively. Relative to their pretreatment values, 50% of the patients receiving BB-10010 completed the treatment with neutrophil values significantly higher than any of the controls (P = .02). Mobilization of GM-CFC was enhanced by BB-10010 with an additional fivefold increase over that generated by chemotherapy alone, giving a maximal 25-fold increase over pretreatment values. Bone marrow progenitor assays before and after this standard regimen of chemotherapy indicated little long-term cumulative impairment to recovery from chemotherapy. Despite the limited cumulative damage to the bone marrow, which may have minimized the protective value of BB-10010 during this regimen of chemotherapy, better recovery of neutrophils in the later treatment cycles with BB-10010 was indicated in a number of patients. 相似文献
73.
Interviews of a representative sample of 201 physicians (general practitioners, gynecologists, pediatricians) with a mean age of 47 years show: there is a unmanageable amount of information about drugs and their risks. The physicians prefer practical experience rather than specialized literature. As a result they plead for a central authority of information with periodical reports on the current knowledge of drug-therapy and with the possibility of therapeutical consultation. 相似文献
74.
LG Cleland 《Canadian Metallurgical Quarterly》1996,35(11):1041-1042
75.
F Liao RL Rabin JR Yannelli LG Koniaris P Vanguri JM Farber 《Canadian Metallurgical Quarterly》1995,182(5):1301-1314
Mig is a chemokine of the CXC subfamily that was discovered by differential screening of a cDNA library prepared from lymphokine-activated macrophages. The mig gene is inducible in macrophages and in other cells in response to interferon (IFN)-gamma. We have transfected Chinese hamster ovary (CHO) cells with cDNA encoding human Mig and we have derived CHO cell lines from which we have purified recombinant human Mig (rHuMig). rHuMig induced the transient elevation of [Ca2+]i in human tumor-infiltrating T lymphocytes (TIL) and in cultured, activated human peripheral blood-derived lymphocytes. No responses were seen in human neutrophils, monocytes, or Epstein-Barr virus-transformed B lymphoblastoid cell lines. rHuMig was chemotactic for TIL by a modified Boyden chamber assay but rHuMig was not chemotactic for neutrophils or monocytes. The CHO cell lines, IFN-gamma-treated human peripheral-blood monocytes, and IFN-gamma-treated cells of the human monocytic cell line THP-1 all secreted multiple and identical HuMig species as revealed by SDS-PAGE. Using the CHO-derived rHuMig, we have shown that the species' heterogeneity is due to proteolytic cleavage at basic carboxy-terminal residues, and that the proteolysis occurs before and not after rHuMig secretion by the CHO cells. The major species of secreted rHuMig ranged from 78 to 103 amino acids in length, the latter corresponding to the full-length secreted protein predicted from the HuMig cDNA. Carboxy-terminal-truncated forms of rHuMig were of lower specific activity compared to full-length rHuMig in the calcium flux assay, and the truncated species did not block the activity of the full-length species. It is likely that HuMig plays a role in T cell trafficking and perhaps in other aspects of the physiology of activated T cells. 相似文献
76.
J Chapman L Cervenáková RB Petersen HS Lee J Estupinan S Richardson CL Vnencak-Jones DC Gajdusek AD Korczyn P Brown LG Goldfarb 《Canadian Metallurgical Quarterly》1998,51(2):548-553
We have identified a member of the VEGF family by computer-based homology searching and have designated it VEGF-D. VEGF-D is most closely related to VEGF-C by virtue of the presence of N- and C-terminal extensions that are not found in other VEGF family members. In adult human tissues, VEGF-D mRNA is most abundant in heart, lung, skeletal muscle, colon, and small intestine. Analyses of VEGF-D receptor specificity revealed that VEGF-D is a ligand for both VEGF receptors (VEGFRs) VEGFR-2 (Flk1) and VEGFR-3 (Flt4) and can activate these receptors. However. VEGF-D does not bind to VEGFR-1. Expression of a truncated derivative of VEGF-D demonstrated that the receptor-binding capacities reside in the portion of the molecule that is most closely related in primary structure to other VEGF family members and that corresponds to the mature form of VEGF-C. In addition, VEGF-D is a mitogen for endothelial cells. The structural and functional similarities between VEGF-D and VEGF-C define a subfamily of the VEGFs. 相似文献
77.
78.
B Cannella CJ Hoban YL Gao R Garcia-Arenas D Lawson M Marchionni D Gwynne CS Raine 《Canadian Metallurgical Quarterly》1998,95(17):10100-10105
Glial growth factor 2 (GGF2) is a neuronal signal that promotes the proliferation and survival of the oligodendrocyte, the myelinating cell of the central nervous system (CNS). The present study examined whether recombinant human GGF2 (rhGGF2) could effect clinical recovery and repair to damaged myelin in chronic relapsing experimental autoimmune encephalomyelitis (EAE) in the mouse, a major animal model for the human demyelinating disease, multiple sclerosis. Mice with EAE were treated with rhGGF2 during both the acute and relapsing phases. Clinically, GGF2 treatment delayed signs, decreased severity, and resulted in statistically significant reductions in relapse rate. rhGGF2-treated groups displayed CNS lesions with more remyelination than in controls. This correlated with increased mRNA expression of myelin basic protein exon 2, a marker for remyelination, and with an increase in the CNS of the regulatory cytokine, interleukin 10, at both the RNA and protein levels. Thus, a beneficial effect of a neurotrophic growth factor has been demonstrated on the clinical, pathologic, and molecular manifestations of autoimmune demyelination, an effect that was associated with increased expression of a T helper 2 cytokine. rhGGF2 treatment may represent a novel approach to the treatment of multiple sclerosis. 相似文献
79.
80.